Table 1.
Patient Characteristics in the Nonstandard Versus Standard Groups
| All Patients (N = 92) | Standard Group (N = 65) | Nonstandard Group (N = 27) | |
|---|---|---|---|
| Clinico-pathologic characteristics | |||
| Median age, y (range) | 64.5 (37-87) | 64 (49-87) | 66 (37-87) |
| Female gender | 44 (48) | 31 (48) | 13 (48) |
| Smoking status, ever | 84 (91) | 58 (89) | 26 (96) |
| ECOG PS | |||
| 0-1 | 75 (82) | 54 (83) | 21 (78) |
| ≥ 2 | 17 (18) | 11 (17) | 6 (22) |
| Histology | |||
| Non-squamous | 70 (76) | 49 (75) | 21 (78) |
| Squamous | 15 (16) | 11 (17) | 4 (15) |
| Poorly differentiated | 7 (8) | 5 (8) | 2 (7) |
| Driver mutation | |||
| KRAS | 33 (36) | 26 (40) | 7 (26) |
| EGFR | 6 (7) | 3 (5) | 3 (11) |
| Others | 3 (3) | 2 (3) | 1 (4) |
| None identified | 40 (43) | 27 (41) | 13 (48) |
| Not assessed | 10 (11) | 7 (11) | 3 (11) |
| PD-L1 TPS, % | |||
| <1 | 24 (26) | 22 (34) | 2 (7) |
| 1-49 | 17 (18) | 9 (14) | 8 (30) |
| ≥50 | 42 (46) | 28 (43) | 14 (52) |
| Not assessed | 9 (10) | 6 (9) | 3 (11) |
| TMB, mut/mB | |||
| <10 | 20 (22) | 16 (25) | 4 (15) |
| ≥10 | 30 (32) | 19 (29) | 11 (41) |
| Not assessed | 42 (46) | 30 (46) | 12 (44) |
| Treatment characteristics | |||
| Line of pembrolizumab | |||
| First line | 65 (71) | 50 (77) | 15 (56) |
| ≥Second line | 27 (29) | 15 (23) | 12 (44) |
| Treatment | |||
| Monotherapy | 41 (45) | 22 (34) | 19 (71) |
| With chemotherapy | 51 (55) | 43 (66) | 8 (29) |
| Treatment center | |||
| BIDMC | 47 (51) | 29 (45) | 18 (67) |
| VMC | 45 (49) | 36 (55) | 9 (33) |
| Median no. of treatment cycles (range) | 8 (4-41) | 6 (4-20) | 14 (6-41) |
| Best response | |||
| Progression | 7 (8) | 6 (9) | 1 (4) |
| Clinical benefit | 83 (90) | 57 (88) | 26 (96) |
| CR | 15 (16) | 12 (19) | 3 (11) |
| PR | 40 (44) | 25 (38) | 15 (56) |
| SD | 28 (30) | 20 (31) | 8 (30) |
| Not available | 2 (2) | 2 (3) | - |
| Any grade irAE, yes | 54 (59) | 35 (54) | 19 (70) |
| ≥Grade 3 irAE, yes | 28 (30) | 21 (32) | 7 (26) |
| Systemic immunosuppression, yes | 41 (45) | 29 (45) | 12 (44) |
Abbreviations: BIDMC = Beth Israel Deaconess Medical Center; CR = complete response; ECOG = Eastern Cooperative Oncology Group; irAE = immune-related adverse events; PR = partial response; PS = performance status; SD = stable disease; TMB = tumor mutational burden; TPS = tumor proportion score; VMC = Vidant Medical Center.
Data are shown as n (%), unless specified.